Komori
Changes in Officers4886ASKA Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

Notice of Assignment of Responsibilities to Directors and Executive Officers

At the Annual General Meeting of Shareholders, the Company transitioned to a company with an Audit and Supervisory Committee, and on the same date determined the responsibilities assigned to its directors, directors serving as Audit and Supervisory Committee Members, and executive officers. One Audit and Supervisory Board Member and one executive officer retired on the same date.

Worth reading
42Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Who is moving to which position

Resolved 24 June 2026 (the Annual General Meeting of Shareholders and the subsequent Board of Directors meeting)

Departing officer

1 item
Date of departureAudit and Supervisory Board Member Chiku Kazuhiro (知久 一博): 24 June 2026; Executive Officer Saito Junichi (齋藤 淳一): 24 June 2026
Chiku Kazuhiro (知久 一博), Saito Junichi (齋藤 淳一)Next role stated
Former PositionAudit and Supervisory Board Member; Executive Officer
New positionRetirement

“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.

Scheduled Appointment Date24 June 2026
Whether the incumbent will remain in office (whether they will retain their position)

Chiku Kazuhiro (知久 一博): will not remain on the Board of Directors; Saito Junichi (齋藤 淳一): will not remain on the Board of Directors

Directors after the change13Number
Shareholders’ meeting approvalApproved at the 5th Annual General Meeting of Shareholders, held on 24 June 2026
Reason for change

The Company transitioned to a company with an Audit and Supervisory Committee at the 5th Annual General Meeting of Shareholders held on 24 June 2026, and at that meeting and the subsequent Board of Directors meeting determined the responsibilities assigned to directors, including directors serving as Audit and Supervisory Committee Members, and executive officers.

Change in Corporate Governance Structure

Transition to a company with an audit and supervisory committee

Who is moving to which position
ItemDetails
Resolution date24 June 2026 (the Annual General Meeting of Shareholders and the subsequent Board of Directors meeting)
Scheduled Appointment Date24 June 2026
Date of departureAudit and Supervisory Board Member Chiku Kazuhiro (知久 一博): 24 June 2026; Executive Officer Saito Junichi (齋藤 淳一): 24 June 2026
Name of departing officerChiku Kazuhiro (知久 一博), Saito Junichi (齋藤 淳一)
Former position of departing officerAudit and Supervisory Board Member; Executive Officer
New position of departing officerRetirement
Whether the incumbent will remain in officeChiku Kazuhiro (知久 一博): will not remain on the Board of Directors; Saito Junichi (齋藤 淳一): will not remain on the Board of Directors
Reason for changeThe Company transitioned to a company with an Audit and Supervisory Committee at the 5th Annual General Meeting of Shareholders held on 24 June 2026, and at that meeting and the subsequent Board of Directors meeting determined the responsibilities assigned to directors, including directors serving as Audit and Supervisory Committee Members, and executive officers.
Number of directors after the change13 (including 7 outside directors)
Change in Corporate Governance StructureTransition to a company with an audit and supervisory committee
Subject to Approval by the General Meeting of ShareholdersApproved at the 5th Annual General Meeting of Shareholders, held on 24 June 2026
Items this document does not state (10)
Name of appointeeAppointee's new positionAppointee's previous positionAppointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeReason for departureReasons for appointmentFiling as an independent officerDetails of organizational changes

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The Company transitioned to a company with an Audit and Supervisory Committee at the Annual General Meeting of Shareholders held on 24 June 2026, and determined the assigned responsibilities at that meeting and the subsequent Board of Directors meeting. No individual reasons were stated for the retirees.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Assignment of Responsibilities to Directors and Executive Officers | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) timely disclosure | Komori